From the Journals
Clinical Guidelines
VA DOD Updates Asthma Framework
The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.
The 2025 clinical practice guideline by the US Department of Veterans Affairs and Department of Defense for asthma management emphasizes anti-inflammatory therapy through inhaled corticosteroids (ICS) as the primary strategy. Based on randomized trials involving approximately 22,000 patients, single-device maintenance and reliever therapy (SMART) significantly reduced severe exacerbations by about one-third. The guideline, aimed at primary care providers, recommends ICS for all patients, excluding short-acting beta-agonists (SABAs) for symptom relief, and focuses on managing co-morbid conditions to enhance asthma control.
1. 2025 guidelines emphasize the use of ICS for asthma management. 2. Single-device therapy significantly reduces severe exacerbations. 3. Avoids SABA-only therapy; focuses on ICS-containing options. 4. Weight loss recommended for obese patients with asthma. 5. Systematic review based on emerging evidence leading to 21 recommendations. 6. Comorbidities must be managed to improve asthma control. 7. Regular spirometry use is not routinely recommended.